Veterinary-Approved Prescription Pituitary and Antidiuretic Medications for Dogs Across the UK (2025) — DDAVP, Vetoryl, Lysodren, Anipryl, and Percorten-V Explained

DDAVP nasal spray holds a top position in this 2025 veterinarian-reviewed list because its intranasal delivery offers rapid, non-invasive management of central diabetes insipidus in dogs, often enabling lower clinic-contact costs and simpler at-home administration than injectable alternatives. Compared with oral desmopressin (Minirin tablets) it typically provides faster and more predictable absorption, and versus hormonal adrenal therapies in the list it addresses a distinct pituitary-mediated water-balance niche rather than adrenal cortisol control.

Vetoryl is the market-leading trilostane capsule for canine hyperadrenocorticism because it combines an established efficacy profile with veterinary support programs and a licensing structure that often streamlines access in the UK, making it a financially pragmatic primary choice for many clinics. Compared with Lysodren (mitotane), Vetoryl generally requires less intensive in-hospital induction and has a clearer monitoring titration pathway, while being more specifically targeted for pituitary-dependent Cushing’s than the broader adrenocorticolytic approach of mitotane.

Lysodren remains a key option for select cases of adrenal-dependent Cushing’s because mitotane’s adrenocorticolytic action can produce durable remission with lower per-tablet cost than some newer agents, though it typically requires more intensive monitoring and hospital-based induction. Compared to Vetoryl, Lysodren can be a cheaper drug-by-cost in some procurement channels but often incurs higher overall management costs and toxicity risk, so vets reserve it for specific clinical scenarios where its mechanism offers a unique advantage.

Anipryl holds its place as a veterinary-reviewed option because selegiline offers a distinct monoamine-oxidase-B mechanism useful for early or mild pituitary-driven Cushing’s and for canine cognitive dysfunction, often with a favorable side-effect and dosing profile. Financially and technically it can be attractive for milder cases or where owners prefer oral therapy with fewer monitoring requirements than trilostane or mitotane, although it is generally less potent for advanced hyperadrenocorticism.

Percorten-V is the leading long-acting injectable mineralocorticoid replacement for hypoadrenocorticism because its monthly dosing improves owner compliance and delivers stable electrolyte control, often reducing the frequency of clinic visits compared with daily oral alternatives. While the upfront cost per injection can be higher than tablets like Florinef, the overall management burden and monitoring costs are frequently lower, making it the practical market-leader choice for many veterinary teams.

Florinef remains a widely used oral fludrocortisone option for dogs with Addisonian disease because it provides flexible daily dosing and simultaneous mineralocorticoid and glucocorticoid effects, which can simplify initial outpatient management and prescribing economics for some owners. Compared with Percorten-V, Florinef typically has a lower per-dose acquisition cost but may lead to higher long-term monitoring and dose-adjustment demands, so veterinarians weigh convenience, cost and clinical stability when choosing between them.